Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of…
Browsing: MRD
We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be…
By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD…
Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude…
Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock,…
Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the…
Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward…
Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in…
The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease…
This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients,…
The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is…
Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute…
The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…
iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…